close

LATEST POSTS from Anne-Lise Berthier

Trend Chart On Innovative BioIndustries – November 7th, 2019

FEATURE STORY ● The Alliance for Regenerative Medicine outlines recommendations to increase the number of European-based ATMP clinical trials GENE THERAPY ● Long-term correction of copper metabolism in WD mice with AAV8 vector delivering truncated ATP7b ● Enhancing the therapeutic potentiel of sulfamidase for the treatment of MPSIIIA DISRUPTIVE TECHNOLOGIES…..

New R&D agreement to expand Ziopharm’s TCR-T Program

New R&D agreement to expand Ziopharm's TCR-T Program Ziopharm Oncology, an immuno-oncology company focused on developing end-to-end cost-effective solutions using its non-viral Sleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy, has concluded a new R&D agreement with MD Anderson Cancer Center. This agreement is related…..

Transforming DNA repair errors into assets

Transforming DNA repair errors into assets A new bioinformatics tool, MHcut, developed by researchers in Kyoto, Japan, and Montreal, Canada, reveals that a natural repair system for DNA damage, microhomology-mediated end joining, is probably far more common in humans than originally assumed. Using MHcut and commercial genome-editing technology, the researchers created…..

Fourth FDA approval for Vertex’s cystic fibrosis medicines

Fourth FDA approval for Vertex's cystic fibrosis medicines The FDA has approved Trikafta™ (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF) in people ages 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which is estimated to represent 90% of…..

New weapons against superbugs

New weapons against superbugs The rapid emergence of antimicrobial resistance is a matter of global concern. According to the WHO, particularly Gram-negative bacteria like Acinetobactebaumannii, Pseudomonas aeruginosa and Enterobacteriaceae that are resistant to the carbapenem and cephalosporin antibiotics, pose a growing threat to human health. These pathogens can cause severe and often life-threatening…..

NEW: LANDSCAPE IN GENE THERAPY COMPANIES 2019

  BioPharmAnalyses and OctopusyX BioConsulting are proud to announce the launch of their up-dated and enriched 2019 edition of their report entitled “Landscape… in Gene Therapy Companies”.  This report provides you with an in-depth analysis of more than 230 companies involved in this expanding field. (UPDATED SEP 2019)   In…..

300 million people living with a rare disease worldwide

300 million people living with a rare disease worldwide An open-access article, written by Orphanet (coordinated by INSERM, the French National Institute of Health and Medical Research), EURORDISRare Diseases Europe and Orphanet Ireland (based at the National Rare Diseases Office, Mater Misericordiae University Hospital, Dublin, Ireland), confirms  the number of…..